These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38650500)

  • 21. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
    Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
    Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risankizumab-induced paradoxical pustular psoriasis.
    McFeely O; Pender E; Victory L; Almutlaq H; Storan E
    Clin Exp Dermatol; 2022 Mar; 47(3):616-617. PubMed ID: 34748673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
    Peccerillo F; Odorici G; Pellacani G; Conti A
    Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination treatment with a tumour necrosis factor antagonist and an oral retinoid: efficacy in severe acral psoriasis?
    Ingram JR; Anstey AV; Piguet V
    Br J Dermatol; 2012 Oct; 167(4):949-51. PubMed ID: 22486276
    [No Abstract]   [Full Text] [Related]  

  • 25. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab.
    Chew AL; Bennett A; Smith CH; Barker J; Kirkham B
    Br J Dermatol; 2004 Aug; 151(2):492-6. PubMed ID: 15327561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
    Assefa GT; Kaneko S; Oguro H; Morita E
    J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
    [No Abstract]   [Full Text] [Related]  

  • 29. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva).
    Thielen AM; Barde C; Saurat JH
    Br J Dermatol; 2006 Oct; 155(4):846-7. PubMed ID: 16965444
    [No Abstract]   [Full Text] [Related]  

  • 31. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 32. Different response rates between palmoplantar involvement and diffuse plaque psoriasis in patients treated with infliximab.
    Brunasso AM; Puntoni M; Delfino C; Massone C
    Eur J Dermatol; 2012; 22(1):133-5. PubMed ID: 22134100
    [No Abstract]   [Full Text] [Related]  

  • 33. Guselkumab: human monoclonal antibody against interleukin-23 for moderate to severe psoriasis.
    Paton DM
    Drugs Today (Barc); 2018 Mar; 54(3):199-207. PubMed ID: 29771254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-23 inhibitors for moderate-to-severe psoriasis.
    Ibler E; Gordon KB
    Semin Cutan Med Surg; 2018 Sep; 37(3):158-162. PubMed ID: 30215632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risankizumab (Skyrizi) for psoriasis.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
    [No Abstract]   [Full Text] [Related]  

  • 36. Successful treatment of severe psoriasis relapse with secukinumab (interleukin 17 A inhibitor) after abrupt brodalumab (interleukin 17 receptor inhibitor) discontinuation: A retrospective study evaluating long-term efficacy and safety.
    Khemis A; Kelati A; Montaudié H; Lacour JP; Passeron T
    J Am Acad Dermatol; 2018 Oct; 79(4):758-760. PubMed ID: 29596876
    [No Abstract]   [Full Text] [Related]  

  • 37. The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study.
    Chiu HY; Tsai TF
    J Am Acad Dermatol; 2016 Jul; 75(1):224-6. PubMed ID: 27317524
    [No Abstract]   [Full Text] [Related]  

  • 38. Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
    van Lingen RG; van Erp PE; Seyger MM; de Jong EM; de Boer-van Huizen RT; Driessen RJ; van de Kerkhof PC
    Acta Derm Venereol; 2009; 89(5):518-20. PubMed ID: 19734982
    [No Abstract]   [Full Text] [Related]  

  • 39. Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.
    Witjes H; Khatri A; Diderichsen PM; Mandema J; Othman AA
    Clin Pharmacol Ther; 2020 Feb; 107(2):435-442. PubMed ID: 31502263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of inverse psoriasis with efalizumab.
    George D; Rosen T
    J Drugs Dermatol; 2009 Jan; 8(1):74-6. PubMed ID: 19180901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.